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Considerable variability exists for the reported mortality 
risk among patients with ST-elevation myocardial infarction 
(STEMI) and who are treated with primary percutaneous co-
ronary intervention (PCI). The diversity in the clinical out-
comes for these patients challenges the physician at each step: 
risk stratification, planning the treatment and monitoring 
the response to PCI. In this regard, the current guidelines for 
the treatment of patients with acute coronary syndrome (ACS) 
recommend risk stratification using a variety of clinical vari-
ables. Clinical variables such as biomarkers, electrocardiogra-
phy (ECG), and the imaging modalities have been studied 
for whether these variables may improve the risk assessment 
and clinical care. The standard 12-lead ECG has been used 
as the single most important diagnostic tool for the evalua-
tion of ACS. Measurement via ECG is very useful and infor-
mative for determining the quality of reperfusion in patients 
with acute STEMI. The degree of ST segment deviation also 
confers prognostic information.
1) Since it was first document-
ed in 1971 in an animal study that the magnitude of ST seg-
ment elevation was well correlated well with depressed myo-
cardial creatine kinase activity as well as myocardial necro-
sis,
2) the degree of ST segment elevation has been used as an 
index of the severity of myocardial ischemic injury. Success-
ful recanalization of the epicardial coronary arteries by PCI 
does not ensure microvascular reperfusion, which is strongly 
correlated with the cardiovascular outcome. The ST-segment 
changes reflect the status of myocardial tissue perfusion, and 
so this may provide prognostic information beyond that sug-
gested by a coronary angiogram.
3) The consistent relation-
ship between the degree of ST resolution and the risk for dea-
th and congestive heart failure in patients who are treated with 
fibrinolytic therapy has been previously reported.
4)5) 
Woo et al.
6) evaluated the resolution of the sum of ST-seg-
ment elevation (sum STR) 60 minutes after primary PCI as 
well as the biochemical markers to determine the prognostic 
value of these indices in patients with STEMI. That study sh-
owed that an incomplete sum STR is associated with a poor 
Killip class, delayed PCI, a decreased ejection fraction and 
increased baseline biomarkers, including high sensitivity C-
reactive protein (hs-CRP), troponin I (TnI) and N-terminal 
pro-B-type natriuretic peptide (NT-proPNP). In that study, 
the degree of the sum STR provided a prognostic factor for ma-
jor adverse cardiac events (MACEs) within 6 months, which 
is consistent with previous observation.
5) Furthermore, the 
addition of biochemical markers such as TnI, NT-proBNP 
and hsCRP to the sum STR improved the prognostic value. 
That study reappraised the importance of the ST resolution 
for predicting MACEs and it emphasized the enhanced pre-
dictive power by combining additional biomarkers. The sum 
STR has been used as a conventional method, yet measuring 
the ST elevations from all the leads is somewhat time con-
suming. Schröder et al.
5) suggested 2 other methods that are 
superior to the conventional sum STR in terms of the predic-
tive accuracy and simplicity (Fig. 1): 1) the ST-segment de-
viation resolution in the single lead that shows the maximum 
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deviation (single-lead STR) and 2) the existing ST-segment 
deviation in the single ECG lead with the maximum devia-
tion at a given time point (max STE). 
Woo et al.
6) determined that hs-CRP is an independent pre-
dictor of MACEs after STEMI, whereas other biomarkers 
such as TnI and NT-proBNP were not as significant indepen-
dent predictors, as assessed by multivariate analysis. Elevated 
CRP is a nonspecific marker of inflammation, and this has 
been associated with poor outcomes in patients with ACS.
7) 
There is only limited data on this and it is restricted to pa-
tients with STEMI. For the patients with Q-wave acute myo-
cardial infarction in 1 cohort study, increased CRP was as-
sociated with complications of acute MI such as left ventri-
cular aneurysm, aggravated heart failure and cardiac death.
8) 
On the other hand, several studies have shown that hs-CRP is 
an independent predictor of the short- and/or long-term out-
come among patients with Non-ST elevation acute coronary 
syndrome.
7) This data may suggest two possibilities. First, el-
evation of CRP during ACS is probably an intensification of 
the inflammatory process and this can contribute to compli-
cations of vulnerable plaque. Second, elevated CRP could be a 
consequence of the inflammation in response of myocardial 
necrosis. However, the precise relationship between CRP and 
the risk in ACS has not yet been conclusively established. 
Cardiac troponin and natriuretic peptide have been assess-
ed for their usage in clinical care. Increased cardiac troponin 
is central to the definition of MI, and an elevated troponin le-
vel on admission is associated with worse outcomes in pa-
tients with STEMI.
1) Natriuretic peptides are released from 
the myocardium in response to stress, and they are increased 
in a variety of cardiovascular diseases, including heart fail-
ure. Elevated levels of natriuretic peptide are strongly associ-
ated with the clinical outcomes in patients with STEMI.
9) How-
ever, there are no clear clinical implications of how an in-
creased natriuretic peptide level should guide specific treat-
ment in patients with ACS. 
In conclusion, analysis of ST-segment resolution as seen 
on standard 12-lead ECG is a rapid, efficient way to assess the 
quality of reperfusion and so this provides prognostic infor-
mation for patients with ACS. Biomarkers such as hsCRP 
and TnI may confer additional prognostic information, to 
some extent, for these patients. However, assessing the levels 
of TnI and natriuretic peptides in ACS patients is still not 
certain with regard to the clinical decision making.
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Fig. 1. The thirty-day cardiac mortality rates by the ST resolution 
risk groups with the ECG recorded at 90 minutes after onset of 
STEMI in 2,719 patients of the InTIME II Study. STR: resolution 
of ST-segment elevation, max STE: the maximum ST-segment 
deviation in a single lead.
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